Publications by authors named "C Belluco"
Article Synopsis
- The study examines the effectiveness and feasibility of rectal-sparing treatments for rectal cancer patients who showed a significant response after neoadjuvant therapy, although there is ongoing debate about their effectiveness.
- In a multicenter study involving 178 patients, around 80.9% were able to preserve their rectum while showing promising survival rates over three years, including an overall survival rate of 80.6% and a stoma-free survival rate of 95%.
- The findings suggest that for rectal cancer patients who achieve a major or complete response to neoadjuvant therapy, rectal preservation is possible in most cases without negatively affecting patient outcomes.
Aim: Local excision (LE) in selected cases after neoadjuvant radiochemotherapy (RCT) for locally advanced rectal cancer in clinically complete or major responders has been recently reported as an alternative to standard radical resection. Completion total mesorectal excision (cTME) is generally performed when high-risk pathological features are found in LE surgical specimens. The aim of this study was to evaluate the incidence of residual tumour and lymph node metastases after cTME in patients previously treated by RCT + LE.
View Article and Find Full Text PDFArticle Synopsis
- The Italian Research Group for Gastric Cancer created a database to assess how a practical approach influences stage IV gastric cancer management and patient outcomes.
- Data from 383 patients collected between 2018 and September 2022 showed increased use of laparoscopic techniques and a significant difference in surgical treatment strategies compared to past practices.
- The study found that while different metastatic sites didn't significantly affect survival rates, having multiple sites did worsen survival, indicating that better diagnosis and staging can improve outcomes for patients eligible for curative surgery.
Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas.
Cancers (Basel)
October 2023
Doxorubicin is a widely used anticancer agent as a first-line treatment for various tumor types, including sarcomas. Its use is hampered by adverse events, among which is the risk of dose dependence. The potential cardiotoxicity, which increases with higher doses, poses a significant challenge to its safe and effective application.
View Article and Find Full Text PDF